Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors
Authors:
- David T. BowenDBDavid T. Bowen
- Paul R. CrockerPCPaul R. Crocker
- 1 February 2007
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 31 (2) , 211-220
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemiaBlood, 2005
- Siglecs in innate immunityCurrent Opinion in Pharmacology, 2005
- Siglecs—the major subfamily of I-type lectinsGlycobiology, 2005
- CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistanceLeukemia, 2004
- Mechanisms controlling pathogenesis and survival of leukemic stem cellsOncogene, 2004
- Siglec-8Journal of Biological Chemistry, 2000
- Identification and Characterization of a Novel Siglec, Siglec-7, Expressed by Human Natural Killer Cells and MonocytesJournal of Biological Chemistry, 1999
- OB-BP1/Siglec-6Journal of Biological Chemistry, 1999
- Characterization of Siglec-5, a Novel Glycoprotein Expressed on Myeloid Cells Related to CD33Blood, 1998
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976